| 引用本文: |
刘杰,苏宝印.参芪清毒胶囊对血液透析患者残余肾功能保护作用的临床观察[J].湖南中医药大学学报,2019,39(1):85-89[点击复制] |
|
| |
|
|
| 本文已被：浏览 2088次 下载 605次 |
| 参芪清毒胶囊对血液透析患者残余肾功能保护作用的临床观察 |
| 刘杰,苏宝印 |
| (河北以岭医院, 河北 石家庄 050091) |
| 摘要: |
| 目的 观察参芪清毒胶囊对血液透析患者残余肾功能（residual renal function，RRF）的保护作用。方法 选取2016年1月~2017年6月在我院行血液透析的慢性肾功能衰竭患者160例，随机分为两组，每组80例。两组患者均给予常规维持性血液透析，对照组采取常规降压、纠正贫血等基础药物治疗，治疗组在对照组基础上加服中成药参芪清毒胶囊。测定两组患者治疗前以及治疗1个月、2个月、3个月和6个月后血肌酐（serum creatinine，Scr）、尿素氮（blood urea nitrogen，BUN）、胱抑素C（Cystatin C，Cys-C）、日均尿量、RRF等指标。结果 治疗前两组患者Scr、BUN、Cys-C比较差异无统计学意义（P>0.05）；治疗1个月后，治疗组Scr、BUN、Cys-C有明显下降（P<0.05），对照组下降不明显（P>0.05）；治疗2个月、3个月和6个月后两组Scr、BUN、Cys-C均有明显下降（P<0.05），且治疗组低于对照组，两组比较差异有统计学意义（P<0.05）。治疗前两组患者日均尿量、RRF比较差异无统计学意义（P>0.05）；治疗1个月后两组日均尿量下降不明显（P>0.05），RRF较治疗前均有明显下降（P<0.05）；治疗2个月、3个月、6个月后两组日均尿量、RRF较治疗前均有明显下降（P<0.05），且对照组下降更为明显，两组比较差异有统计学意义（P<0.05）。结论 参芪清毒胶囊联合常规血液透析治疗可以保护慢性肾功能衰竭患者RRF，增加尿量，缓解病情，具有一定临床推广意义。 |
| 关键词: 参芪清毒胶囊 血液透析 残余肾功能 血肌酐 尿素氮 胱抑素C |
| DOI：10.3969/j.issn.1674-070X.2019.01.020 |
| 投稿时间：2018-09-11 |
| 基金项目:河北省中医药管理局科研计划项目（2010114）。 |
|
| Protective Effect of Shenqi Qingdu Capsule on Residual Renal Function in Hemodialysis Patients |
| LIU Jie,SU Baoyin |
| (Hebei Yiling Hospital, Shijiazhuang, Hebei 050091, China) |
| Abstract: |
| Objective To investigate the protective effect of Shenqi Qingdu Capsule on residual renal function in hemodialysis patients.Methods A total of 160 patients with chronic renal failure who underwent hemodialysis in our hospital from January 2016 to June 2017 were equally and randomly divided into control group and treatment group. The control group was given routine maintenance hemodialysis, routine antihypertensive drug, and anemia correction drug, while the treatment group was given Shenqi Qingdu Capsule in addition to the treatment for the control group. The levels of serum creatinine (SCr), blood urea nitrogen (BUN), and cystatin C (Cys-C), daily urine volume, and residual renal function (RRF) were measured in both groups before treatment and after 1, 2, 3, and 6 months of treatment.Results Before treatment, there were no significant differences in levels of SCr, BUN, and Cys-C between the two groups (P>0.05). After one month of treatment, the treatment group showed significant decreases in levels of SCr, BUN, and Cys-C (P<0.05), while the control group showed no significant decreases in the above indices (P>0.05). After 2, 3, and 6 months of treatment, both groups showed significant decreases in levels of SCr, BUN, and Cys-C (P<0.05), and the treatment group had significantly lower levels of SCr, BUN, and Cys-C compared with the control group (P<0.05). Before treatment, there were no significant differences in daily urine volume and RRF between the two groups (P>0.05). After one month of treatment, both groups showed no significant decrease in daily urine volume (P>0.05), while they showed a significant decrease in RRF (P<0.05). After 2, 3, and 6 months of treatment, both groups showed significant decreases in daily urine volume and RRF (P<0.05), and the control group had significantly greater decreases in the two indices compared with the control group (P<0.05).Conclusion For patients with chronic renal failure, Shenqi Qingdu Capsule combined with routine hemodialysis can protect RRF, increase urine volume, and alleviate the condition, so it has a certain clinical significance. |
| Key words: Shenqi Qingdu Capsule hemodialysis residual renal function serum creatinine urea nitrogen cystatin C |
|
二维码（扫一下试试看！） |
|
|
|
|
